Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q1 2023 Earnings Presentation
6 slides from Genedx's earnings presentation, May 9, 2023
Slide 1: One Test: Miss Less. Discover More. 1Q 2023 Earnings Presentation
One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 1Q 2023 Earnings Presentation May 9, 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: Our mission: deliver personalized and actionable health insights
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
Slide 4: 1Q 2023 and Recent Highlights
1Q 2023 and Recent Highlights Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue included $22.4 million in whole exome testing, representing a 22% increase year over year Ongoing cost mitigation efforts delive
Slide 5: Strong Momentum Across Pro Forma Volume & Revenue from Continuing Operations
Strong Momentum Across Pro Forma Volume & Revenue from Continuing Operations Q1 2023 Volume Mix Q1 2023 Revenue Mix1 WES/WGS 17% Other Tests 27% Exome Based 6% WES/WGS Hereditary 57% Cancer Hereditary Other Tests 13% Cancer 64% 11% Exome Based 5% ~53k tests Q1 total volume $39.4M Q1 total revenue fr
Slide 6: 2023 Guidance
2023 Guidance Revenues between $205-220 million for full year 2023 v 2023 and beyond Expanded adjusted gross margin profile Use of net $95-110 million in cash in 2023 for continuing operations Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-